SCHEMBL25834148

SCHEMBL25834148

C=C1CCC(N2CCc3ccccc32)C(=O)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.49
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
GFER P55789 3/20 0.47
CRBN Q96SW2 6/20 0.46
DDB1 Q16531 2/20 0.46
LMNA P02545 1/20 0.44
ROCK2 O75116 1/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 1/20 0.40
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19359331 0.86 CRBN (0.62) GAAALDH1A1KDM4EMAPTGFER
SCHEMBL29923129 0.86 CRBN (0.62) GAAALDH1A1KDM4EMAPTGFER
SCHEMBL22158607 0.78 CRBN (0.59) GAAALDH1A1KDM4EMAPTCRBN
SCHEMBL22158608 0.78 CRBN (0.59) GAAALDH1A1KDM4EMAPTCRBN
SCHEMBL22158644 0.78 CRBN (0.59) GAAALDH1A1KDM4EMAPTCRBN
SCHEMBL25036761 0.77 HTR6 (0.47) ALDH1A1KDM4EMAPTHTR2CHTR2B
SCHEMBL17753358 0.77 CRBN (0.76) ALDH1A1CRBNDDB1TSHRCHRM2
SCHEMBL20324930 0.74 CRBN (0.64) ALDH1A1CRBNDDB1TSHRCHRM2
SCHEMBL11829199 0.72 CRBN (0.52) GAAALDH1A1KDM4EMAPTGFER
SCHEMBL411456 0.72 CRBN (0.71) ALDH1A1CRBNDDB1TSHRCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB GAA 2081/4885ALDH1A1 4309/4885KDM4E 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.